BTIG raised the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $27 and keeps a Buy rating on the shares. The company hosted a webcast to discuss updated Phase 1a/1b data for BTK degrader bexobrutideg in r/r chronic lymphocytic leukemia patients presented at ASH this weekend, and aside from compelling mPFS of 22.1 months and mDOR of 20.1 months in phase 1a, and dose dependent Objective Response Rate observed in the 600mg phase 1b cohort, the firm comes away noting how encouraged key opinion leader Dr. Alencar was on bexdeg’s “remarkable” tolerability and efficacy, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics Reports Promising Data at Hematology Meeting
- Nurix Therapeutics presents data from Phase 1 trial of bexobrutideg
- Nurix presents new clinical data from Phase 1a/1b NX-5948-301 study
- Nurix Therapeutics assumed with a Buy at Truist
- Nurix Therapeutics price target lowered to $22 from $30 at JPMorgan